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WE HAVE SHOWN previously that combined but not discrete transient perioperative blockade of 
CD28!B7 and CD40/gp39 costimulatory pathways results in 
indefinite prolongation of islet allograft survival.! Similar 
observations have also been made in the realm of solid 
organ transplantation (TX).2 Additionally, the use of both 
rhCTLA4-Ig and anti-gp39 mAb (but not alone) have also 
resulted in abrogation of morphologic changes considered 
pathognomonic of posttransplant vasculopathy.3 Although 
the profound immunosuppressive effects of contemporane-
ous blockade of both costimulatory pathways have been 
established, not evident, however, are the underlying cellu-
lar mechanism(s) responsible for the observed outcome. 
The present study was therefore designed to address the 
latter issue. 
MATERIALS AND METHODS 
Animals 
Inbred male Mis-disparate DBN2 (H_2d; MISd; V(36- TcR) and 
C3H (H-2k; Mise; V(36+ TcR) mice were used as donors and 
recipients of islet cell Tx, respectively. The recipients were ren-
dered diabetic by previous (day - 4) treatment with streptozotocin 
(300 mglkg IV). 
Recipient Treatment and Follow-Up 
Subsequent to islet cell Tx, the animals were treated with either 
rhCTIA4-1g (group I; 200 ILg on days 0, 2, 4, and 6 post-Tx 1M) or 
anti-gp39 mAb (group II; 250 ILg on days 0, 2, and 4 post-Tx IP). 
Additionally, in a distinct set of animals, these two molecules were 
also used contemporaneously (group III), as were isotype-matched 
irrelevant control antibodies (group IV). In animals with long-term 
euglycemia, the presence of donor-specific tolerance (DST) was 
ascertained by transplanting donor and third-part» skin allografts. 
In the latter group of animals, in vitro analysis (flow cytometry, 
one-way MLR, suppressor cell, and TcR cross-linking assays) were 
also performed. 
RESULTS AND DISCUSSION 
As has been documented previously/ animals in groups I, 
II, and IV had comparable graft survivals with recurrence of 
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hyperglycemia (in the majority of recipients) within 26 days 
post-islet Tx. On the contrary, indefinite (> 180 days) islet 
allograft survival was witnessed in all animals in group III. 
These animals also had evidence of stable DST, for they 
rejected third-party but not donor skin allografts when 
challenged on -d120 post-islet Tx. The deletion of autore-
active V(36+ TcR-bearing T cells in DBN2 but not C3H 
mice during ontogeny provided a tool that was used as a 
surrogate marker to delineate the cellular mechanisms 
underlying the observed outcome. Interestingly, while no 
peripheral deletion of V (36 + CD4 + T cells was evident in 
animals in group III, there was marked reduction in their 
proliferative response when exposed to anti-V(36 mAb in a 
TcR cross-linking assay. This latter observation suggested 
that clonal anergy but not deletion is perhaps the predom-
inant mechanism. responsible for indefinite islet and chal-
lenge skin allograft survival witnessed in recipients treated 
with a short contemporaneous perioperative course of 
rhCTLA4-Ig and anti-gp39 mAb. The long-term stability of 
the observed DST in these animals is currently being 
investigated. 
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